Tonix Pharm Holdings (TNXP) Stock Price, Quote & News

Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for...

Industry: Biotechnology

Sector: Healthcare

Phone: 862 799 8599

Fax: 862 904 8163

Website: www.tonixpharma.com

Address:

26 Main Street, Suite 101, Chatham, United States

Adubstradesmini Aug. 26 at 5:42 PM

$GRRR stick to $TNXP broke bot

0 · Reply

Terminator1 Aug. 26 at 5:42 PM

$TNXP let’s hope it is manipulation before a buyout. BUT 1-looks like it’s more of a lack of preparedness and poor execution after fda approval 2- allowing mms back in at much cheaper sp after massive dump around $65+ 3- who the heck knows

0 · Reply

rigretti Aug. 26 at 5:42 PM

$TNXP boy was I wrong on my expectations after approval 😁. But still believe in it. Would be ridiculous if they fuck up now. Hope the directions pay attention at the investors. I saw a lot of legit questions.

0 · Reply

Sabo75 Aug. 26 at 5:38 PM

$TNXP huge drug Not sure why it’s struggling after approval. Manipulation before buyout. Hmmmm

3 · Reply

BiotechBonesaw Aug. 26 at 5:33 PM

$TNXP fake news from a FUDder.

1 · Reply

mikeyb0810 Aug. 26 at 5:31 PM

$TNXP Loved this stock initially, but it’s turned out to be a dog. I work in the pharmaceutical industry, and the reality is that insurance companies don’t care — they’re not going to cover the brand-name price for this drug. Pharmacies just interchange it with the generic that’s been around forever, the $10 version! So there’s really no market traction for this. Sorry Bulls, find another stock.

0 · Reply

Rbnhoodsfinest Aug. 26 at 5:29 PM

$TNXP i just bought more. Like .29 of a share.

0 · Reply

BiotechBonesaw Aug. 26 at 5:28 PM

$TNXP buying more shares. 💎 🤛 🚀

0 · Reply

azazelhazel Aug. 26 at 5:26 PM

$TNXP

0 · Reply

StockJayC Aug. 26 at 5:21 PM

$TNXP The idea for this company is sentiment shift for investors - this is how it should have gone: 1: Huge media attention, Seth increase social media presence and gaining partnerships for their fibro platform 2: Scheduled investor presentations for approval, revenue forecast, pricing, partnerships or at least a timeline 3: NO RAISING CAPITAL PRE APPROVAL (WHAT INSANITY TO DO THAT) Raise capital on the huge run up after approval 4: Then the investor meeting should outline the raising (not wanting to increase share count as drastically - prioritise investors) 5: Then the GTM updates and in-depth strategy

0 · Reply

Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)

Aug 16, 2025, 8:45 AM EDT - 10 days ago

Tonix Secures Fibromyalgia Approval - What Investors Should Know

Aug 15, 2025, 3:50 PM EDT - 10 days ago

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

Aug 15, 2025, 3:44 PM EDT - 10 days ago

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Aug 11, 2025, 4:15 PM EDT - 14 days ago

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

Jul 21, 2025, 7:00 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Jul 10, 2025, 7:00 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Jul 9, 2025, 4:01 PM EDT - 6 weeks ago

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Jul 7, 2025, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Jul 2, 2025, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Jun 30, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 16, 2025, 11:30 AM EDT - 2 months ago

Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

Jun 16, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

Jun 13, 2025, 7:30 AM EDT - 2 months ago

Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?

Jun 13, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

Jun 10, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention

Jun 5, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025

May 22, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

May 21, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

May 14, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

May 12, 2025, 4:30 PM EDT - 3 months ago

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Apr 29, 2025, 9:05 AM EDT - 4 months ago

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Apr 24, 2025, 7:55 AM EDT - 4 months ago

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Apr 16, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

Apr 9, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

Apr 7, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Apr 2, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition

Mar 31, 2025, 7:00 AM EDT - 5 months ago

Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

Mar 27, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Mar 26, 2025, 2:30 AM EDT - 5 months ago

Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years

Mar 25, 2025, 8:16 AM EDT - 5 months ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

ARQT

Mar 24, 2025, 8:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Mar 20, 2025, 7:00 AM EDT - 5 months ago

As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

Mar 19, 2025, 8:15 AM EDT - 5 months ago

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

ABSI HQY

Mar 18, 2025, 4:30 PM EDT - 5 months ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Mar 13, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025

Mar 12, 2025, 7:30 AM EDT - 5 months ago

Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target

Mar 11, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

Mar 10, 2025, 8:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company's Single-Dose Mpox and Smallpox Vaccine Candidate

Mar 5, 2025, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

Mar 4, 2025, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

Feb 7, 2025, 8:30 AM EST - 7 months ago

Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash

Feb 6, 2025, 8:00 AM EST - 7 months ago

Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

Feb 5, 2025, 7:00 AM EST - 7 months ago

Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference

Feb 4, 2025, 7:00 AM EST - 7 months ago

Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer

Feb 3, 2025, 8:05 AM EST - 7 months ago

Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split

Dec 23, 2024, 8:00 AM EST - 8 months ago

Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia

Dec 17, 2024, 10:59 AM EST - 9 months ago

FDA accepts Tonix's NDA for non-opioid fibromyalgia drug TNX-102 SL

Dec 17, 2024, 8:00 AM EST - 9 months ago

Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

Adubstradesmini Aug. 26 at 5:42 PM

$GRRR stick to $TNXP broke bot

0 · Reply

Terminator1 Aug. 26 at 5:42 PM

0 · Reply

rigretti Aug. 26 at 5:42 PM

0 · Reply

Sabo75 Aug. 26 at 5:38 PM

$TNXP huge drug Not sure why it’s struggling after approval. Manipulation before buyout. Hmmmm

3 · Reply

BiotechBonesaw Aug. 26 at 5:33 PM

$TNXP fake news from a FUDder.

1 · Reply

mikeyb0810 Aug. 26 at 5:31 PM

0 · Reply

Rbnhoodsfinest Aug. 26 at 5:29 PM

$TNXP i just bought more. Like .29 of a share.

0 · Reply

BiotechBonesaw Aug. 26 at 5:28 PM

$TNXP buying more shares. 💎 🤛 🚀

0 · Reply

azazelhazel Aug. 26 at 5:26 PM

$TNXP

0 · Reply

StockJayC Aug. 26 at 5:21 PM

0 · Reply

PMR617 Aug. 26 at 5:17 PM

$TNXP They must be super diluting. Shorting is one thing. This has to be dilution.

0 · Reply

BBatteries Aug. 26 at 5:13 PM

$TNXP Jeez. Just touch $29 to make the algorithms happy . Let’s get this over with so we can march back to $60

0 · Reply

StockJayC Aug. 26 at 5:11 PM

$TNXP Look again bullish on the pipeline but following onto this. Anyone who really thought it was getting denied is crazy - The drug had a improved safety profile and lower dosage with better efficacy. Once the positive trials were confirmed it was just a matter of completing submission correctly and it's confirmed in managements eyes. Management have been completely silent since approval other than the shoddy conference and 0 indication on future updates. I will stand corrected if they have some huge announcement with a game changing partner or acquisition then I apologise. However, if we see some shitty partner or a 3rd party sales team then this is clear that it's a last minute (Shit we haven't got anything) decision. Until then, I will be holding and not buying unless we get down to sub 30s (As to which we will be nearing cash on hand)

0 · Reply

T2HeadedEagle Aug. 26 at 5:04 PM

$TNXP wake me up when this hits $20

0 · Reply

TraderNice Aug. 26 at 5:01 PM

$TNXP The stock PGEN was approved the same day as TNXP. Couple days after their approval they gave detailed commercialization information, TNXP has not. PGEN took a dip after approval but since then the price has improved sharply. TNXP needs to provide a PR on their commercialization….this is very important

1 · Reply

StockJayC Aug. 26 at 5:00 PM

$TNXP Quick rant: Still holding strong Not 1 post about the FDA approval on Seths LinkedIn (Yikes) No posts about the fibro platform (Yet he is passionate about this space?) Piss poor business plan as of right now (Couldn't convert at targent so why can he think he can do do the same here with a higher TAM) No market projections Unbelievably bullish on the pipeline and new TN102-SL but management need to get their arse in gear. Now you have the CFO, completely out of his depth and no chance he can manage a $1B+ company. I have calculated projections in a day from online sources of the fibro market with projections on 3 case scenarios. I don't think he even knows how to do a financial forecast and is stuck with only being about the do basic accounts and accruals from contracts. None of his experience suggests he has the skillset to do anything other than box standard budgeting and temporary contract works) https://www.linkedin.com/in/bradleysaenger/

2 · Reply

geniuscali Aug. 26 at 4:57 PM

$TNXP

0 · Reply

Proposition_Joe Aug. 26 at 4:56 PM

$TNXP it comes down to this- what is a *reasonable* timeframe for releasing pricing and further details and forecasts related to commercialization? I believe 30 days from approval is a reasonable timeframe to expect such details. Now, what did I want to happen, as opposed to what did happen, is details of pricing in the post-approval conference call. I also wanted there to have been a batch run of product for free samples to be distributed after approval but prior to full production runs and distribution in Q4. And yes, I wanted there to have been some partnership and licensing agreements in place for worldwide markets and US market assistance too. That is what a successful launch conference call could have looked like on 8/18 that would have kept the share price rising. I don’t necessarily begrudge Seth for not guiding sales number on that call because almost no biotech would guide revenue that early. I do begrudge them not releasing pricing. I would like Seth to step aside as CEO.

1 · Reply

Buylowfordoe Aug. 26 at 4:55 PM

$TNXP here is what I sent

1 · Reply

TraderNice Aug. 26 at 4:55 PM

$TNXP I have traded this stock over a year and it does need volume to move up, I have seen this over and over during the summer….watch the level 2! This stock is part of my portfolio, and I love the medicine but do not trust management…I’m a long term investor with this stock…just watch.

0 · Reply

MedicineMan777 Aug. 26 at 4:49 PM

$TNXP Only 700k shares traded today is not dilution folks! It is manipulation called stealing shares from weak hands!

0 · Reply

Fueler Aug. 26 at 4:47 PM

$TNXP Better start writing!

1 · Reply

Market Cap	332.93M
Revenue (ttm)	10.09M
Net Income (ttm)	-130.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,288.80%
Debt to Equity Ratio	0.00

Volume	812,069
Avg Vol	1,477,522
Day's Range	N/A - N/A
Shares Out	8.77M
Stochastic %K	2%
Beta	1.70
Analysts	Strong Sell
Price Target	$60.00